Evidence map›Paper›PMID 37698922›Full record

Observational studyJCI insight2023

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease.

Alexander V Sorokin, Christin G Hong, Angel M Aponte, Elizabeth M Florida, Jingrong Tang, Nidhi Patel, Irina N Baranova, Haiou Li, Philip M Parel, Vicky Chen and 9 more

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01621594 (Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01621594 narecruitingnot on this map

Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2012 to 2027Enrolled5,000ConditionsCoronary DiseaseArmsCannon Aquilion ONE CT system
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction-Associated Steatotic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 4 countries.

Alexander V SorokinSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Christin G HongSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Angel M AponteProteomics Core, and.
Elizabeth M FloridaSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Jingrong TangSection of Lipoprotein Metabolism, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, USA.
Nidhi PatelSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Irina N BaranovaDepartment of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland, USA.
Haiou LiSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Philip M ParelSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Vicky ChenBioinformatics/Integrated Data Sciences Section, Research Technology Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Sierra R WilsonSection of Lipoprotein Metabolism, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, USA.
Emily L OngstadBioscience Cardiovascular, Research and Early Development, and.
Anna CollénProjects, Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Martin P PlayfordSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Thomas L EggermanDepartment of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland, USA.
Marcus Y ChenSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch.
Kazuhiko KotaniDivision of Community and Family Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Alexander V BocharovDepartment of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland, USA.
Alan T RemaleySection of Lipoprotein Metabolism, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, USA.
Inflammation Research Foundation · USNational Heart Lung and Blood Institute · USNational Institutes of Health Clinical Center · USAbterra Biosciences (United States) · USAstraZeneca (Poland) · PLBioscience Research · USJichi Medical University · JPNational Institute of Allergy and Infectious Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOxidized apolipoprotein B (oxLDL) and oxidized ApoA-I (oxHDL) are proatherogenic. Their prognostic value for assessing high-risk plaques by coronary computed tomography angiography (CCTA) is missing.

methodsIn a prospective, observational study, 306 participants with cardiovascular disease (CVD) had extensive lipoprotein profiling. Proteomics analysis was performed on isolated oxHDL, and atherosclerotic plaque assessment was accomplished by quantitative CCTA.

resultsPatients were predominantly White, overweight men (58.5%) on statin therapy (43.5%). Increase in LDL-C, ApoB, small dense LDL-C (P < 0.001 for all), triglycerides (P = 0.03), and lower HDL function were observed in the high oxLDL group. High oxLDL associated with necrotic burden (NB; β = 0.20; P < 0.0001) and fibrofatty burden (FFB; β = 0.15; P = 0.001) after multivariate adjustment. Low oxHDL had a significant reverse association with these plaque characteristics. Plasma oxHDL levels better predicted NB and FFB after adjustment (OR, 2.22; 95% CI, 1.27-3.88, and OR, 2.80; 95% CI, 1.71-4.58) compared with oxLDL and HDL-C. Interestingly, oxHDL associated with fibrous burden (FB) change over 3.3 years (β = 0.535; P = 0.033) when compared with oxLDL. Combined Met136 mono-oxidation and Trp132 dioxidation of HDL showed evident association with coronary artery calcium score (r = 0.786; P < 0.001) and FB (r = 0.539; P = 0.012) in high oxHDL, whereas Met136 mono-oxidation significantly associated with vulnerable plaque in low oxHDL.

conclusionOur findings suggest that the investigated oxidized lipids are associated with high-risk coronary plaque features and progression over time in patients with CVD.

trial registrationCLINICALTRIALS: gov NCT01621594.

fundingNational Heart, Lung, and Blood Institute at the NIH Intramural Research Program.

Indexed as

Cardiovascular DiseasesPlaque, AtheroscleroticApolipoprotein A-IApolipoprotein B-100Apolipoproteins BCholesterol, LDLHumansMaleProspective StudiesAPOA1 protein, humanAPOB protein, humanApolipoprotein A-IApolipoprotein B-100Apolipoproteins BCholesterol, LDLAtherosclerosisCardiologyCardiovascular diseaseInflammationLipoproteins

Identifiers

PMID37698922
PMCPMC10619497
OpenAlexW4386648702

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.